AKT1 and COVID-19: Consistently, it has been proposed that targeting AKT can inhibit entry and replication of SARS-CoV-2, modulate the immune response, suppress the cytokine storm, and protect against thrombosis associated with severe COVID-19 cases [119, 197, 199].